Fevipiprant

Drug Profile

Fevipiprant

Alternative Names: NVP-QAW-039; QAW-039; QAW39A; QAW39A2107

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class Acetic acids; Anti-inflammatories; Antiallergics; Antiasthmatics; Pyridines; Pyrroles
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Allergic asthma; Asthma
  • Phase II Atopic dermatitis
  • No development reported Allergic rhinitis

Most Recent Events

  • 24 Jul 2017 Novartis plans a phase III trial for Asthma (NCT03226392)
  • 14 Jul 2017 Novartis Pharmaceuticals plans a phase III trial for Asthma (In adolescents, In adults, In the elderly, Adjunctive treatment) (NCT03215758)
  • 27 Mar 2017 Novartis plans a phase I trial in patients with Renal failure and in Healthy volunteers (NCT03087942)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top